https://european-biotechnology.net/wp-content/uploads/2026/01/EBSIN-Summer_2025_Techparks_960x540.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-07 11:52:162026-01-07 13:32:03Amgen selects German Disco Pharma to collaborate in multi-million-dollar deal
https://european-biotechnology.net/wp-content/uploads/2026/01/pawel-czerwinski-prMn9KINLtI-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-06 18:06:152026-01-06 18:06:15Amgen acquires Dark Blue Therapeutics for up to $840 million
https://european-biotechnology.net/wp-content/uploads/2026/01/pexels-savvas-stavrinos-270619-814544-1030x686-1.jpg6861030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-06 10:37:272026-01-06 10:37:27Servier and Insilico sign an $888 million AI oncology discovery deal
https://european-biotechnology.net/wp-content/uploads/2025/12/MFN9.webp359800Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-12-22 08:17:232025-12-22 08:17:23Nine Big Pharma to cut US drug prices in Most-favoured Nations deals
https://european-biotechnology.net/wp-content/uploads/2025/12/Clarivate-e1766397076442-1030x443-1.png4431030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-12-20 09:49:162025-12-20 09:49:16Trump Administration tables new version of Biosecure Act
https://european-biotechnology.net/wp-content/uploads/2025/12/FDA-White-Oak-Building-01.jpg220420Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2025-12-19 10:41:062025-12-19 10:41:06Egetis Therapeutics AB submits rolling NDA for tiratricol
